Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Non Operating Income: 2014-2025

Historic Non Operating Income for Northwest Biotherapeutics (NWBO) over the last 10 years, with Sep 2025 value amounting to -$12.5 million.

  • Northwest Biotherapeutics' Non Operating Income fell 173.54% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.9 million, marking a year-over-year decrease of 289.66%. This contributed to the annual value of -$17.3 million for FY2024, which is 143.55% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Non Operating Income stood at -$12.5 million for Q3 2025, which was down 1,988.31% from -$599,000 recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Non Operating Income ranged from a high of $144.0 million in Q4 2021 and a low of -$17.2 million during Q3 2022.
  • In the last 3 years, Northwest Biotherapeutics' Non Operating Income had a median value of -$2.0 million in 2025 and averaged -$3.6 million.
  • In the last 5 years, Northwest Biotherapeutics' Non Operating Income skyrocketed by 219.92% in 2023 and then plummeted by 934.68% in 2024.
  • Northwest Biotherapeutics' Non Operating Income (Quarterly) stood at $144.0 million in 2021, then tumbled by 107.03% to -$10.1 million in 2022, then surged by 111.51% to $1.2 million in 2023, then plummeted by 934.68% to -$9.7 million in 2024, then tumbled by 173.54% to -$12.5 million in 2025.
  • Its last three reported values are -$12.5 million in Q3 2025, -$599,000 for Q2 2025, and -$2.0 million during Q1 2025.